Domain EYEION.com for sale! This premium domain is available now at Kadomain.com

No support found for dual antiplatelet therapy after cardiac bypass surgery over aspirin alone

  • medicalxpress.com language
  • 2025-09-02 02:18 event
  • 2 weeks ago schedule
No support found for dual antiplatelet therapy after cardiac bypass surgery over aspirin alone
Dual antiplatelet therapy after cardiac bypass surgery is no more effective than acetylsalicylic acid alone and also increases the risk of serious bleeding. This is shown in a study by researchers at Karolinska Institutet and the University of Gothenburg published in the journal the New England Journal of Medicine.

1.214. Global inequalities found in cancer research funding

  • 2 weeks ago schedule
  • medicalxpress.com language

Researchers at the University of Southampton examining worldwide variations in funding for cancer research say there's a pressing need to invest more in lower income countries.

1.215. Intravenous blood thinner investigated in cardiogenic shock caused by acute myocardial infarction

  • 2 weeks ago schedule
  • medicalxpress.com language

Compared with crushed ticagrelor, intravenous cangrelor provided immediate, effective platelet inhibition, with no increase in major bleeding and lower mortality rates in patients with acute myocardial infarction and cardiogenic shock, according to late-breaking research presented in a Hot Line session at the ESC Congress 2025.

1.216. Personalized risk messages fail to boost colorectal cancer screening participation in trial

  • 2 weeks ago schedule
  • medicalxpress.com language

A randomized controlled trial aimed to determine whether providing information on patient risk for advanced colorectal neoplasia (ACN) to patients and providers affects colorectal cancer (CRC) screening uptake.

1.217. H. pylori screening does not significantly reduce upper gastrointestinal bleeding after heart attack, trial finds

  • 2 weeks ago schedule
  • medicalxpress.com language

Routine Helicobacter pylori screening did not significantly reduce the risk of upper gastrointestinal bleeding in patients hospitalized for myocardial infarction (MI), according to late-breaking research presented in a Hot Line session at the ESC Congress 2025 and simultaneously published in JAMA.

1.218. Anticoagulation offers no clear benefit in patients with device-detected atrial fibrillation

  • 2 weeks ago schedule
  • medicalxpress.com language

A Win Ratio analysis confirmed the primary result of the NOAH—AFNET 6 trial and did not find an advantage of anticoagulation with edoxaban over no anticoagulation in patients with device-detected atrial fibrillation. Clinical decisions should therefore be guided by individual factors. The findings were presented by Dr. Nina Becher, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, in a hotline session at the annual congress of the European Society of Cardiology (ESC) in Madrid.

1.219. Patient-operated ECGs reveal AF burden predicts long-term outcomes during early rhythm control

  • 2 weeks ago schedule
  • medicalxpress.com language

An analysis of patient-operated ECGs from the EAST—AFNET 4 trial revealed: A low AF burden below 6% in the first year of early rhythm control therapy was associated with low cardiovascular event rates during the subsequent 4 years of follow-up. Patients with a higher AF burden on early rhythm control suffered more AF-related events. The findings were presented by AFNET board member Prof. Ulrich Schotten, Maastricht University, in a hotline session at the annual congress of the European Society of Cardiology (ESC) in Madrid.

1.220. Fascin-1 protein identified as driver of cervical cancer spread and drug resistance

  • 2 weeks ago schedule
  • medicalxpress.com language

Cervical cancer remains one of the most common malignancies in women, ranking as the fourth most prevalent cancer worldwide. Most cases are caused by high-risk strains of human papillomavirus (HPV), particularly HPV16 and HPV18.

1.221. Olezarsen reduces levels of the blood fat, triglycerides, in patients at high cardiovascular risk: Clinical trial

  • 2 weeks ago schedule
  • medicalxpress.com language

Olezarsen decreased levels of triglycerides compared with placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, according to a late-breaking trial presented in a Hot Line session at the ESC Congress 2025 and simultaneously published in the American Heart Journal.

1.222. Clinical trial finds pulsed field ablation was not superior to radiofrequency ablation in paroxysmal atrial fibrillation

  • 2 weeks ago schedule
  • medicalxpress.com language

Pulsed field ablation did not have superior efficacy to radiofrequency ablation in patients with drug-resistant paroxysmal (intermittent) atrial fibrillation, according to results from a late-breaking trial presented in a Hot Line session at the ESC Congress 2025.

1.223. No support found for dual antiplatelet therapy after cardiac bypass surgery over aspirin alone

  • 2 weeks ago schedule
  • medicalxpress.com language

Dual antiplatelet therapy after cardiac bypass surgery is no more effective than acetylsalicylic acid alone and also increases the risk of serious bleeding. This is shown in a study by researchers at Karolinska Institutet and the University of Gothenburg published in the journal the New England Journal of Medicine.

1.224. Clinical trial finds aficamten is superior to metoprolol for symptomatic obstructive hypertrophic cardiomyopathy

  • 2 weeks ago schedule
  • medicalxpress.com language

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to late-breaking research presented in a Hot Line session at ESC Congress 2025 and simultaneously published in the New England Journal of Medicine.

1.225. Exploring criminal behavior in patients with dementia

  • 2 weeks ago schedule
  • medicalxpress.com language

A suspected perpetrator who can barely remember his name, several traffic violations committed by a woman in her mid-fifties who is completely unreasonable and doesn't understand her behavior—should such cases be brought before a court? And how does the state deal with people who commit acts of violence without meaning to?

1.226. Neuroscientists show for first time that precise timing of nerve signals determines how brain processes information

  • 2 weeks ago schedule
  • medicalxpress.com language

It has long been known that the brain preferentially processes information that we focus our attention on—a classic example is the so-called cocktail party effect.

1.227. A potential new Blue Zone: Region in Finland stands out for its populace's longevity

  • 2 weeks ago schedule
  • medicalxpress.com language

Swedish-speaking Ostrobothnia in Finland stands out as a potential Blue Zone, thanks to factors such as long life expectancy, good health and a lifestyle resembling those in well-known Blue Zones. Åland, which boasts the highest life expectancy and best health, fails to meet the lifestyle principles of Blue Zones, except when it comes to providing a pleasant environment, according to a study from Åbo Akademi University.

1.228. Routine heart CT scanning is not warranted after stenting for left main coronary artery disease, trial results indicate

  • 2 weeks ago schedule
  • medicalxpress.com language

Routine coronary computed tomography (CCT)-based follow-up after percutaneous coronary intervention (PCI) of the left main coronary artery did not reduce death, myocardial infarction (MI), unstable angina or stent thrombosis compared with symptom-based follow-up, according to late-breaking research presented in a Hot Line session at the ESC Congress 2025.

1.229. Blood-pressure lowering effects of zilebesiran found in hypertensive patients at high cardiovascular risk

  • 2 weeks ago schedule
  • medicalxpress.com language

Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a 5-mmHg reduction in systolic blood pressure at Month 3 compared with placebo, a difference that did not reach statistical significance. These results were presented as a late-breaking trial in a Hot Line session today at ESC Congress 2025.

1.230. Evidence appears supportive for the initiation of SGLT2 inhibitors in patients hospitalized for heart failure

  • 2 weeks ago schedule
  • medicalxpress.com language

In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects were seen when combining trial data, according to late-breaking research presented in a Hot Line session at ESC Congress 2025. Findings were also published in the journal Circulation.

1.231. Digital twin-guided ablation reduces arrhythmia recurrence in persistent atrial fibrillation, clinical trial finds

  • 2 weeks ago schedule
  • medicalxpress.com language

Adding digital twin-guided ablation to a standard ablation technique improved outcomes in patients with persistent atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session at the ESC Congress 2025.

1.232. New data to guide the treatment of patients with multivessel coronary artery disease

  • 2 weeks ago schedule
  • medicalxpress.com language

Noninferiority was not demonstrated between immediate and staged complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease undergoing percutaneous coronary intervention (PCI), according to late-breaking research presented in a Hot Line session at the ESC Congress 2025 and simultaneously published in The Lancet.

Cookie Policy

We use cookies and similar technologies to help the site provide a better user experience. By using the website you agree to our Cookie Policy, Terms of Use and Privacy Policy.